Catalyst Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for rare and difficult-to-treat diseases. Its recurring updates center on the commercial performance of FIRDAPSE® (amifampridine), AGAMREE® (vamorolone), and FYCOMPA® (perampanel), along with financial results, revenue guidance, conference presentations, and business updates.
Company news also covers product-specific medical and legal developments, including vamorolone research in Duchenne muscular dystrophy and patent litigation settlements involving FIRDAPSE. Additional announcements address patient advocacy initiatives, support services, and strategic portfolio activity tied to Catalyst’s U.S.-based rare-disease commercial model.
Catalyst Pharmaceuticals (Nasdaq:CPRX) reported Q1 2026 net product revenue of $149.3 million, up 5.6% year over year. FIRDAPSE and AGAMREE combined revenue rose 28.2% to $135.6 million, while FYCOMPA declined 61.3% after loss of exclusivity.
GAAP net income was $63.7 million ($0.50 diluted EPS), and non-GAAP net income was $100.3 million ($0.79 diluted EPS). Cash and equivalents reached $755.9 million with no funded debt. Catalyst will not provide forward-looking guidance or hold a Q1 earnings call.
Catalyst Pharmaceuticals (Nasdaq: CPRX) canceled its previously scheduled first quarter 2026 earnings conference call and webcast for May 12, 2026 at 8:30 AM ET because of a pending acquisition by Angelini Pharma S.p.A. The company will release Q1 2026 results after market close on Monday, May 11, 2026.
The cancellation removes the live Q&A session; financial results will still be published as planned on May 11.
Catalyst Pharmaceuticals (Nasdaq: CPRX) and licensor SERB reached a settlement with Hetero and affiliates resolving patent litigation over FIRDAPSE (amifampridine) 10 mg tablets. Under the Agreement, Hetero may not market a U.S. generic earlier than a specified date in January 2035, if FDA-approved. All related U.S. district court cases will be terminated before the May 18, 2026 trial date, and the confidential settlement will be submitted to the U.S. FTC and DOJ for review.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release first quarter 2026 financial results after market close on May 11, 2026 and will host a conference call and webcast on May 12, 2026 at 8:30 AM ET to discuss results and provide a business update.
The webcast will be available in the Investors section of the company's website and a replay will remain accessible for at least 30 days.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will present multiple real‑world poster analyses of vamorolone in Duchenne muscular dystrophy and sponsor an MDA Industry Forum with Santhera at the 2026 MDA Clinical & Scientific Conference in Orlando.
Key events: three poster presentations on March 8, 2026 (6:00–8:00 PM ET) and a sponsored symposium on March 10, 2026 (12:00–1:30 PM ET) in the Hilton Orlando Key Largo Room.
Catalyst Pharmaceuticals (Nasdaq: CPRX) reported record full year 2025 total revenues of $589.0 million, a 19.8% increase, and Q4 2025 revenues of $152.6 million. GAAP net income was $214.3 million; cash and cash equivalents were $709.2 million at year-end.
The company provided 2026 guidance of $615 million to $645 million in total revenues, with FIRDAPSE expected at $435M–$450M and AGAMREE at $140M–$150M. Catalyst announced a $200 million share repurchase program and completed substantial buybacks in 2025.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:30 PM ET.
Management led by President and CEO Rich Daly will webcast the presentation; the webcast is available via the company investor website and a replay will be accessible for at least 30 days.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release fourth quarter and full-year 2025 financial results after market close on February 25, 2026. Management will host a conference call and webcast on February 26, 2026 at 8:30 AM ET to discuss results and provide a business update.
Dial-in numbers are provided for US/Canada and international callers, and the webcast will be available in the Investors section at www.catalystpharma.com. A replay will remain on the website for at least 30 days following the event.
Catalyst Pharmaceuticals (Nasdaq: CPRX) and The University of Notre Dame announced the inaugural Catalyst Advocacy Scholars Summit (CASS), a week-long immersive program for 12 students enrolled in Notre Dame’s Patient Advocacy Minor.
The summit runs January 5–9, 2026 in Coral Gables, Fla., and is designed to educate students on patient advocacy and biopharmaceutical operations while giving Catalyst access to student perspectives on its programs. Catalyst said it aims to attract talent to the industry and increase patient focus across scientific degree programs.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced that President and CEO Rich Daly and other management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:45pm PST. The presentation will be webcast from the company’s investor website and a replay will be available for at least 30 days.
The company described itself as a commercial-stage biopharmaceutical focused on in-licensing, developing, and commercializing therapies for rare and difficult-to-treat diseases.